Citius Oncology, Inc. (CTOR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Citius Oncology, Inc. (CTOR) has a cash flow conversion efficiency ratio of -0.113x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.97 Million) by net assets ($35.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CTOR net asset quality score to measure how much of total assets are equity-financed.
Citius Oncology, Inc. - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Citius Oncology, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Citius Oncology, Inc. (CTOR) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Citius Oncology, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Citius Oncology, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Export Packing
KO:002200
|
0.002x |
|
Broad Capital Acquisition Corp
NASDAQ:BRAC
|
0.008x |
|
Saehwa IMC Co Ltd
KO:145210
|
0.026x |
|
The Investment Trust Of India Limited
NSE:THEINVEST
|
-0.433x |
|
Context Therapeutics Inc
NASDAQ:CNTX
|
-0.219x |
|
Peoplein Ltd
AU:PPE
|
-0.001x |
|
American Creek Resources Ltd
V:AMK
|
-0.114x |
|
Kandi Technologies Group Inc
NASDAQ:KNDI
|
-0.359x |
Annual Cash Flow Conversion Efficiency for Citius Oncology, Inc. (2022–2025)
The table below shows the annual cash flow conversion efficiency of Citius Oncology, Inc. from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see Citius Oncology, Inc. market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $44.87 Million | $-5.49 Million | -0.122x | -4570.02% |
| 2024-09-30 | $46.14 Million | $126.35K | 0.003x | +111.63% |
| 2023-09-30 | $25.54 Million | $-601.30K | -0.024x | -1680.38% |
| 2022-09-30 | $36.27 Million | $-47.97K | -0.001x | -- |
About Citius Oncology, Inc.
Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidia… Read more